BIOLARGO, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.3515 USD | +4.93% |
|
+12.59% | +109.23% |
| Apr. 02 | Transcript : BioLargo, Inc., Q4 2023 Earnings Call, Apr 02, 2024 | |
| Apr. 01 | BioLargo, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Financials (USD)
| Sales 2024 * | 19.05M | Sales 2025 * | 25.76M | Capitalization | 104M |
|---|---|---|---|---|---|
| Net income 2024 * | -1M | Net income 2025 * | - | EV / Sales 2024 * | 5.46 x |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 4.04 x |
| P/E ratio 2024 * |
-33.5
x | P/E ratio 2025 * |
-
| Employees | 32 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 85.75% |
More Fundamentals
* Assessed data
More news
Latest transcript on BioLargo, Inc.
More press releases
| 1 day | +4.93% | ||
| 1 week | +12.59% | ||
| Current month | -0.96% | ||
| 1 month | +2.03% | ||
| 3 months | +67.30% | ||
| 6 months | +106.76% | ||
| Current year | +109.23% |
1 week
0.31
0.35
1 month
0.290.36
Current year
0.160.45
1 year
0.150.45
3 years
0.150.45
5 years
0.100.45
10 years
0.101.24
| Managers | Title | Age | Since |
|---|---|---|---|
Dennis Calvert
CEO | Chief Executive Officer | 61 | 02-05-31 |
| Director of Finance/CFO | 68 | 08-01-31 | |
| Chief Operating Officer | 55 | 02-05-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Dennis Marshall
BRD | Director/Board Member | 81 | 06-04-27 |
Kenneth Code
CTO | Chief Tech/Sci/R&D Officer | 77 | 07-03-31 |
Dennis Calvert
CEO | Chief Executive Officer | 61 | 02-05-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-22 | 0.335 | -1.36% | 179,674 |
| 24-04-19 | 0.3396 | +7.99% | 175,745 |
| 24-04-18 | 0.3145 | +0.72% | 205,401 |
| 24-04-17 | 0.3122 | -5.16% | 353,124 |
| 24-04-16 | 0.3292 | -0.46% | 212,795 |
Delayed Quote OTC Markets, April 23, 2024 at 03:43 pm EDT
More quotes
BioLargo, Inc. is a cleantech and life sciences innovator and engineering services solution provider. The Company invents, develops, and commercializes platform technologies to solve challenging environmental problems like polyfluoroalkyl substances (PFAS) contamination, advanced water and wastewater treatment, industrial odor control, air quality control, infection control, and myriad environmental remediation challenges. The Companyâs segments include ONM Environmental, which manufactures and sells its odor and VOC control products and services, including its flagship product, CupriDyne Clean; BLEST, which provides professional engineering services supporting its internal business units; Clyra Medical, which develops and sells medical products based on its technology; BioLargo Canada, which is primary engaged in research and development activities; and Corporate Operations, which support the operating segments with legal, accounting, human resources, and other services.
Sector
Commodity Chemicals
Calendar
2024-05-14
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.335
USD
Average target price
0.35
USD
Spread / Average Target
+4.48%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +109.23% | 98.55M | |
| +8.20% | 105B | |
| -4.43% | 63.12B | |
| +10.00% | 37.4B | |
| +39.05% | 37.26B | |
| +5.75% | 32.74B | |
| +6.72% | 19.24B | |
| +11.92% | 16.92B | |
| +15.49% | 15.13B | |
| +5.60% | 14.99B |
- Stock Market
- Equities
- BLGO Stock
